drugset / Trial / NCT02499900

Study to Assess Medication Satisfaction in Patients With Relapsing Remitting Multiple Sclerosis Treated With Copaxone®

NCT02499900 ↗

Phase 4 Completed 861 enrolled Teva Branded Pharmaceutical Products R&D, Inc.
RandomizedParallel-groupOpen-labelTreatment

Summary

The primary objective of this study is to compare patient medication satisfaction as measured by the Medication Satisfaction Questionnaire (MSQ) scores between the Copaxone 40 mg/mL three time a week (TIW) group and the Copaxone 20 mg/mL once daily (QD) group over 6 months of treatment.

Timeline

Start
2015-08-10
Primary completion
2017-01-10
Completion
2017-06-02

Outcome

Met primary endpoint

paper Patients on GA40 were statistically significantly more satisfied with their medication than those on GA20 (LSM difference in MSQ, 0.3; 95% CI, 0.2, 0.5; p<0.001). PMID 31132664 ↗

Drugs

EvaluationDrugModalityDoseRoute
Subject Glatiramer Acetate Small molecule 20 mg/ml Subcutaneous
Subject Glatiramer Acetate Small molecule 40 mg/ml Subcutaneous

Indications